Biomarkers as Diagnostic and Prognostic Tools for Hemophilic Arthropathy
Hämostaseologie · 11.05.2026
DOI: 10.1055/a-2858-0048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 11.05.2026. Verfasst von Lynn M Knowles und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Saarland, Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland, Germany, Homburg.
Abstract (Originalsprache)
AbstractRepeated joint bleeds cause hemophilic arthropathy, which can develop despite regular prophylaxis with clotting factors. Therefore, recognizing ongoing or subclinical bleeds is an important element of assessing the therapeutic needs of patients with hemophilia. Joint bleeds lead to the remodeling of the synovia and subsequent osteochondral damage if bleeding persists or recurs. These processes can be demonstrated by biomarkers in the synovial fluid, blood, or urine, in addition to conventional imaging. Biomarkers that are upregulated in patients with hemophilia in the context of joint bleeds and synovitis are markers of fibrinolysis, inflammation and angiogenesis while markers of extracellular matrix degradation indicate osteochondral damage. Blood-induced inflammation and cartilage damage of the joint correlates with the release of iron-generated reactive oxygen species, IL-1β, and tumor necrosis factor α, which in turn induce the expression of IL-6 and C-reactive protein. Joint bleeds can also cause the release of the endothelial basement membrane markers C4M and Pro-C4 into the blood circulation. Upregulation of biomarkers of osteochondral damage, such as CTX-II, cartilage oligomeric matrix protein, and CS846, results from the dissolution of collagen type 2 and associated proteoglycans in the extracellular matrix of the cartilage. These biomarkers have been shown to indicate blood-induced inflammation, angiogenesis, and cartilage dysfunction but their capacity to predict critical milestones such as the transition to synovia hypertrophy or osteochondral damage needs to be assessed. Further research is necessary to resolve the natural history of hemophilic arthropathy and to provide patients with hemophilia with novel tools to predict disease and treatment outcomes.
Autor:innen und Institutionen
- University of Saarland, Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland, Germany, Homburg.
- University Hospital Augsburg, Institute for Transfusion Medicine and Hemostasis, Bavaria, Germany, Augsburg.
ORCID-Profile: Lynn M Knowles
Zitieren
APA
Knowles, L. M., Laux, L., & Pilch, J. (2026). Biomarkers as Diagnostic and Prognostic Tools for Hemophilic Arthropathy. Hämostaseologie. https://doi.org/10.1055/a-2858-0048
Vancouver
Knowles LM, Laux L, Pilch J. Biomarkers as Diagnostic and Prognostic Tools for Hemophilic Arthropathy. Hämostaseologie. 2026. doi:10.1055/a-2858-0048
BibTeX
@article{Knowles2026,
author = {Knowles, Lynn M and Laux, Lisa and Pilch, Jan},
title = {Biomarkers as Diagnostic and Prognostic Tools for Hemophilic Arthropathy},
journal = {Hämostaseologie},
year = {2026},
doi = {10.1055/a-2858-0048}
}
EUVIMED